NeuroAge Therapeutics
The Science Behind NeuroAge
Brain aging begins decades before symptoms appear. As neurons age, mitochondrial function declines, energy production in brain cells becomes less efficient, and the cellular machinery for clearing damaged proteins and maintaining synaptic connections gradually falters, creating the biological conditions in which neurodegeneration takes hold. NeuroAge was built on a single premise that dementia is not inevitable, and the window for meaningful intervention opens long before the disease does.
Validated on data from 500,000+ individuals·Supported by dozens of peer-reviewed publications·Funded by the Alzheimer’s Drug Discovery Foundation
01 — Overview
Multi-modal assessment outperforms any single measurement
Get your NeuroAge assessment →
The brain ages through overlapping biological processes. Neurons lose connections, blood vessels accumulate damage, inflammatory signaling increases, and energy metabolism in brain cells becomes less efficient, and no single biomarker captures all of these processes at once.
Research published across multiple cohorts and measurement types consistently shows that combining brain imaging, blood-based molecular data, cognitive performance, and genetics explains more variance in dementia risk than any one of these measurements alone. A well-powered study using transcriptomic and neuroimaging data from the same individuals demonstrated that a model incorporating RNA signatures alongside MRI measures explained substantially more of the variance in cognitive function than either approach in isolation, particularly for global cognitive function and executive ability (Wang et al., 2022, Brain Communications).
Predictive accuracy: individual measures vs. combined assessment
Illustrative model performance (AUC) based on published multi-modal brain aging studies
Based on Wang et al. (2022) and multi-modal aging clock literature
This is consistent with the broader principle that dementia is a multi-pathway disease. Alzheimer’s, vascular dementia, and Parkinsonian syndromes share overlapping biological signatures even as they differ in their clinical presentation. An assessment designed to track early brain aging across these shared pathways is more informative than one calibrated to a single disease endpoint. NeuroAge’s four-component approach reflects this understanding, and its ongoing clinical trial is generating data to validate the combined model prospectively.
02 — Biological Age and Dementia Risk
Why biological brain age is a stronger predictor of dementia than chronological age
03 — Cognitive Testing
NeuroGames: cognitive performance as a brain aging clock
04 — Brain Imaging
Brain MRI volumetrics: what your brain structure reveals
05 — Blood Biomarkers
RNA blood biomarkers: a brain-specific aging clock found nowhere else
06 — Genomics
Genetic Resilience: a comprehensive view of dementia and longevity genetics
07 — Plasma Biomarkers
Blood-based Alzheimer's biomarkers through Quest Diagnostics
08 — Clinical Validation
NeuroAge's ongoing clinical study, funded by the Alzheimer's Drug Discovery Foundation
09 — Personalized Interventions
Building personalized brain health interventions from multi-modal data
10 — Reversibility
The evidence that biological brain aging can be slowed and reversed
11 — Personalized Recommendations
How recommendations are generated from your biomarkers
References
- Talboom et al. (2021). Two separate, large cohorts reveal potential modifiers of age-associated variation in visual reaction time performance. npj Aging and Mechanisms of Disease, 7, 14.
- Talboom et al. (2019). Family history of Alzheimer’s disease alters cognition and is modified by medical and genetic factors. eLife, 8, e46179.
- Rentz et al. (2023). Face Name Associative Memory Exam and biomarker status in the ARMADA study. Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring, 15, e12473.
- Sims JR et al. (2023). Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA.
- Irmady K et al. (2023). Blood transcriptomic signatures associated with molecular changes in the brain and clinical outcomes in Parkinson’s disease. Nature Communications, 14, 3956.
- Cummings J and Kinney J (2022). Biomarkers for Alzheimer’s disease: context of use, qualification, and roadmap for clinical implementation. Medicina, 58(7), 952.
- Edwards et al. (2017). Speed of processing training results in lower risk of dementia. Alzheimer’s and Dementia: Translational Research and Clinical Interventions, 3(4), 603–611.
- Glorioso CA et al. (2019). Rate of brain aging and APOE ε4 are synergistic risk factors for Alzheimer’s disease. Life Science Alliance, 2(3), e201900303.
- Glorioso C et al. (2011). Brain molecular aging, promotion of neurological disease and modulation by sirtuin 5 longevity gene polymorphism. Neurobiology of Disease, 41(2), 279–290.
- Wang Q et al. (2022). Deep learning-based brain transcriptomic signatures associated with the neuropathological and clinical severity of Alzheimer’s disease. Brain Communications, 4(1), fcab293.
- Qi X et al. (2020). White matter hyperintensities and risks of cognitive impairment and dementia: A meta-analysis of 36 prospective studies. Neuroscience and Biobehavioral Reviews.
- Zhou W et al. (2022). White matter hyperintensities volume and cognition: A meta-analysis. Frontiers in Aging Neuroscience.
- Gons RAR et al. (2015). White matter and hippocampal volume predict the risk of dementia: The RUN DMC Study.
- Brown R et al. (2022). Longitudinal changes of white matter hyperintensities in sporadic small vessel disease: a systematic review and meta-analysis. Neurology, 99(14), e1500–e1510.
- Wardlaw JM et al. (2017). White matter hyperintensity reduction and outcomes after minor stroke. Neurology, 89(10), 1003–1010.
- BrainKey – AI-powered brain MRI volumetrics platform, Stanford-founded.
- Bopp KL and Verhaeghen P (2005). Aging and verbal memory span: A meta-analysis. Journal of Gerontology: Psychological Sciences, 60(5), P223–P233.
- Horn MM, Kennedy KM, Rodrigue KM (2018). Association between subjective memory assessment and associative memory performance. Psychology and Aging, 33(1), 109–118.
- Enriquez-Geppert S et al. (2021). I know your face but can’t remember your name: Age-related differences in the FNAME-12NL. Archives of Clinical Neuropsychology, 36, 844–849.
- Barnes J et al. (2015). Alzheimer’s disease first symptoms are age dependent: evidence from the NACC dataset. Alzheimer’s and Dementia, 11(11), 1349–1357.
- Bilgel M et al. (2017). Temporal order of Alzheimer’s disease-related cognitive marker changes in BLSA and WRAP longitudinal studies. Journal of Alzheimer’s Disease, 59(4), 1335–1347.
- Vogelgsang J et al. (2024). Plasma amyloid beta X-42/X-40 ratio and cognitive decline in suspected early and preclinical Alzheimer’s disease. Alzheimer’s and Dementia, 20(8), 5132–5142.
- Racke MK et al. (2024). Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer’s disease assessment. Journal of Investigative Medicine.
- Barthélemy NR et al. (2024). Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests. Nature Medicine, 30, 1085–1095.
- Khalafi M et al. (2025). Diagnostic accuracy of phosphorylated tau 217 in detecting Alzheimer’s disease pathology among cognitively impaired and unimpaired: a systematic review and meta-analysis. Alzheimer’s and Dementia, 21(2), e14458.
- Racke MK et al. (2025). Development and clinical validation of blood-based multibiomarker models for the evaluation of brain amyloid pathology. Neurology Clinical Practice.
- Vernooij MW et al. (2007). Incidental findings on brain MRI in the general population. New England Journal of Medicine, 357(18), 1821–1828.
- Nguyen T et al. (2025). Brain age gap as a predictive biomarker that links aging, lifestyle, and neuropsychiatric health. PubMed.
- Liang WS et al. (2022). Assessing brain and biological aging trajectories associated with Alzheimer’s disease. Frontiers in Neuroscience, 16, 1036102.
- Huguet J et al. (2024). The mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline. Lancet Healthy Longevity.
- Erickson KI et al. (2011). Exercise training increases size of hippocampus and improves memory. PNAS, 108(7), 3017–3022.
- Ten Brinke LF et al. (2015). Aerobic exercise increases hippocampal volume in older women with probable mild cognitive impairment: a 6-month randomized controlled trial. British Journal of Sports Medicine, 49(4), 248–254.
- Livingston G et al. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet, 404, 572–628.
- Chene G et al. (2025). Broadening dementia risk models: building on the 2024 Lancet Commission report for a more inclusive global framework. eBioMedicine.
- Andrews SJ et al. (2024). Dementia prevention: the Mendelian randomisation perspective. Journal of Neurology, Neurosurgery and Psychiatry.
- Liu L et al. (2024). Mendelian randomization analysis reveals causal factors behind Alzheimer’s disease risk. Genomics and Precision Medicine.
- Fan M et al. (2023). Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer’s disease. BMJ Open.
- Narayana PA et al. (2023). Toward precision medicine using a digital twin approach: modeling the onset of disease-specific brain atrophy in individuals with multiple sclerosis. Scientific Reports.
- Wickramasinghe N et al. (2022). Digital twins to enable better precision and personalized dementia care. Frontiers in Aging Neuroscience.
- Ornish D, Madison C, Kivipelto M et al. (2024). Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer’s disease: a randomized, controlled clinical trial. Alzheimer’s Research and Therapy, 16, 122.